接受异基因造血细胞移植的成人CMML患者管理:EBMT PH&G委员会推荐
该推荐由欧洲血液与骨髓移植学会(EBMT)实践协调与指南(PH&G)委员会组织专家组制定,基于国际调查、文献综述和专家意见,针对慢性粒单核细胞白血病(CMML)成人患者接受异基因造血细胞移植(allo-HCT)的患者选择、移植时机、移植前策略、移植方式及移植后管理提出首个最佳实践推荐。核心信息是:一旦患者被确定为移植候选者,无论骨髓原始细胞计数如何,应尽可能优先进行 upfront 移植,而不先给予疾病修饰治疗,以最大化达到 allo-HCT 的机会。
要点
- 一旦确定为移植候选者,无论骨髓原始细胞计数如何,应优先进行 upfront 移植而不先给予疾病修饰治疗。
- 推荐基于国际调查、文献综述和专家意见,经结构化讨论和推荐传阅后形成。
- 推荐涵盖患者选择、移植时机、移植前策略、移植方式及移植后管理的流程图。
核心结论
- 核心信息是:一旦患者被确定为移植候选者,无论骨髓原始细胞计数如何,应尽可能优先进行 upfront 移植,而不先给予疾病修饰治疗,以最大化达到 allo-HCT 的机会。
研究设计与样本
- 欧洲血液与骨髓移植学会(EBMT)实践协调与指南(PH&G)委员会组织专家组制定推荐,基于国际调查结果、全面文献综述及专家意见,经结构化讨论和推荐传阅后形成。
主要发现
- 推荐涵盖患者选择、疾病过程中 allo-HCT 时机、移植前策略、allo-HCT 方式以及移植后管理的流程图。
关键数值与推荐
- 一旦患者被确定为移植候选者,无论骨髓原始细胞计数如何,应尽可能优先进行 upfront 移植,而不先给予疾病修饰治疗(原文未给出推荐强度标签)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic myelomonocytic leukemia (CMML) is a heterogeneous disease presenting with either myeloproliferative or myelodysplastic features. Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only potentially curative option, but the inherent toxicity of this procedure makes the decision to proceed to allo-HCT challenging, particularly because patients with CMML are mostly older and comorbid. Therefore, the decision between a nonintensive treatment approach and allo-HCT represents a delicate balance, especially because prospective randomized studies are lacking and retrospective data in the literature are conflicting. International consensus on the selection of patients and the ideal timing of allo-HCT, specifically in CMML, could not be reached in international recommendations published 6 years ago. Since then, new, CMML-specific data have been published. The European Society for Blood and Marrow Transplantation (EBMT) Practice Harmonization and Guidelines (PH&G) Committee assembled a panel of experts in the field to provide the first best practice recommendations on the role of allo-HCT specifically in CMML. Recommendations were based on the results of an international survey, a comprehensive review of the literature, and expert opinions on the subject, after structured discussion and circulation of recommendations. Algorithms for patient selection, timing of allo-HCT during the course of the disease, pretransplant strategies, allo-HCT modality, as well as posttransplant management for patients with CMML were outlined. The keynote message is, that once a patient has been identified as a transplant candidate, upfront transplantation without prior disease-modifying treatment is preferred to maximize chances of reaching allo-HCT whenever possible, irrespective of bone marrow blast counts.
引用
- Onida F, Gagelmann N, Chalandon Y, et al. Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee. Blood. 2024. PMID: 38493484. doi:10.1182/blood.2023023476
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。